Glycosides of Nadifloxacin-Synthesis and Antibacterial Activities against Methicillin-Resistant Staphylococcus aureus

被引:0
作者
Hutchins, Mark [1 ]
Bovill, Richard A. [1 ]
Stephens, Peter J. [1 ]
Brazier, John A. [2 ]
Osborn, Helen M. I. [2 ]
机构
[1] ThermoFisher Sci, Wade Rd, Basingstoke RG24 8PW, Hants, England
[2] Univ Reading, Reading Sch Pharm, Whiteknights, Reading RG6 6AD, Berks, England
关键词
Staphylococcus aureus; MRSA; nadifloxacin; glycoside; DERIVATIVES; OPC-7251;
D O I
10.3390/molecules27051504
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The increase in the number of bacteria that are resistant to multiple antibiotics poses a serious clinical problem that threatens the health of humans worldwide. Nadifloxacin (1) is a highly potent antibacterial agent with broad-spectrum activity. However, its poor aqueous solubility has limited its use to topical applications. To increase its solubility, it was glycosylated herein to form a range of trans-linked (3a-e) and cis-linked (7a,b) glycosides, each of which was prepared and purified to afford single anomers. The seven glycoside derivatives (3a-e, 7a,b) were examined for potency against eight strains of S. aureus, four of which were methicillin-resistant. Although less potent than free nadifloxacin (1), the alpha-L-arabinofuransoside (3a) was effective against all strains that were tested (minimum inhibitory concentrations of 1-8 mu g/mL compared to 0.1-0.25 mu g/mL for nadifloxacin), demonstrating the potential of this glycoside as an antibacterial agent. Estimation of Log P as well as observations made during preparation of these compounds reveal that the solubilities of the glycosides were greatly improved compared with nadifloxacin (1), raising the prospect of its use in oral applications.
引用
收藏
页数:16
相关论文
共 21 条
[11]   Plant Glycosides and Glycosidases: A Treasure-Trove for Therapeutics [J].
Kytidou, Kassiani ;
Artola, Marta ;
Overkleeft, Herman S. ;
Aerts, Johannes M. F. G. .
FRONTIERS IN PLANT SCIENCE, 2020, 11
[12]   Medical progress -: Staphylococcus aureus infections [J].
Lowy, FD .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (08) :520-532
[13]   Efficacy and Safety of Nadifloxacin for Bacterial Skin Infections: Results from Clinical and Post-Marketing Studies [J].
Narayanan V. ;
Motlekar S. ;
Kadhe G. ;
Bhagat S. .
Dermatology and Therapy, 2014, 4 (2) :233-248
[14]   Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections [J].
Nenoff, P ;
Haustein, UF ;
Hittel, N .
CHEMOTHERAPY, 2004, 50 (04) :196-201
[15]  
Otto Michael, 2010, Expert Rev Dermatol, V5, P183, DOI 10.1586/edm.10.6
[16]  
Patel M.V., 2004, Antibacterial Optically Pure Benzoquinolizine Carboxylic Acids, Processes, Compositions and Methods of Treatment, Patent No. [U.S. 6,750,224B1, 6750224]
[17]   First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital [J].
Ploy, MC ;
Grélaud, C ;
Martin, C ;
de Lumley, L ;
Denis, F .
LANCET, 1998, 351 (9110) :1212-1212
[18]   A Salmochelin S4-Inspired Ciprofloxacin Trojan Horse Conjugate [J].
Sanderson, Thomas J. ;
Black, Conor M. ;
Southwell, James W. ;
Wilde, Ellis J. ;
Pandey, Apurva ;
Herman, Reyme ;
Thomas, Gavin H. ;
Boros, Eszter ;
Duhme-Klair, Anne-Kathrin ;
Routledge, Anne .
ACS INFECTIOUS DISEASES, 2020, 6 (09) :2532-2541
[19]   Design and Evaluation of Microemulsion Gel System of Nadifloxacin [J].
Shinde, Ujwala ;
Pokharkar, Sharda ;
Modani, Sheela .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 74 (03) :237-247
[20]  
STEWART GT, 1963, BRIT MED J, P308